Rapport Therapeutics, Inc.
RAPPNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $1.23B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $23.75$52.93
- Volume (live)
- -
- Avg. volume (3M)
- 812.36K
Rapport Therapeutics (RAPP) Stock Price & Financial Analysis
Rapport Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $25.71 - $27.76 |
|---|---|
| 52-Week High | $52.93 |
| 52-Week Low | $23.75 |
| Open | $27.54 |
| Volume (last close) | 1.19M |
| Average Volume (3M) | 812.36K |
| Revenue (TTM) | 20.00M |
|---|---|
| Net Income (TTM) | -137.16M |
| Free Cash Flow (TTM) | -97.15M |
| EPS (TTM) | −$3.05 |
| Profit Margin | -685.80% |
| Operating Margin | -767.58% |
| Return on Equity (ROE) | -32.43% |
| Debt to Equity | 0.02 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.23B |
|---|---|
| Shares Outstanding | 47.47M |
| Price to Sales (P/S) | 61.55 |
| Price to Book (P/B) | 2.91 |
| EV/EBITDA | -8.14 |
| 50-Day MA | $40.37 |
|---|---|
| 200-Day MA | $35.76 |
| 1-Year Change | +1.30% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Rapport Therapeutics at a Glance
As of the Oct 23, 2026 close, Rapport Therapeutics (RAPP) has a market capitalization of $1.23B. The stock trades at 61.5× sales. Over the trailing twelve months it lost $137.16M on revenue of $20.00M and burned $97.15M of free cash flow.
As of its latest reported balance sheet, it holds $63.61M in cash and securities against $10.11M of debt, a net cash position of $53.51M.
Rapport Therapeutics does not currently pay a dividend.
The share price is up 1.3% over the past year. At $25.93 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $23.75 to $52.93, below its 200-day moving average of $35.76.
Based on 16 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $69.00, 166.1% above the Oct 23, 2026 close.
Frequently Asked Questions About Rapport Therapeutics
What is the current stock price for RAPP?
As of the Oct 23, 2026 close, RAPP stock trades at $25.93. The 52-week range is $23.75–$52.93, with a day range of $25.71–$27.76.
What is the P/E ratio for RAPP?
The P/E ratio (Price-to-Earnings) for RAPP is shown in the Key Statistics section. This valuation metric helps compare Rapport Therapeutics, Inc. to industry peers.
Does RAPP pay dividends?
Rapport Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for RAPP?
Based on ratings from 16 professional analysts over the last 90 days, the consensus for RAPP is Buy. The average 12-month price target is $69.00, a 166.1% upside from the Oct 23, 2026 close of $25.93.
What is the market cap of RAPP?
As of the Oct 23, 2026 close, Rapport Therapeutics's market capitalization is $1.23B, classifying it as a small-cap company. Rapport Therapeutics operates in the Healthcare sector within the Biotechnology industry.